CMV Infection or Reactivation After Allogenic HSCT
Conditions
Keywords
CMV infection, CMV reactivation, allogenic HSCT, GVHD prophylaxis, posttransplant cyclophosphamide (PTCy), cyclosporin A, methotrexate
Brief summary
The goal of this observational study is to compare the CMV infection and reactivation after allogeneic hematopoietic stem cell transplantation Between Standard Regimen, Methotrexate plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen. The main questions it aims to answer are: * How do CMV infection and reactivation differ between Allo-SCT patients who received a standard regimen versus those who received a Post-transplant Cyclophosphamide-based regimen? * progression-free survival, Median overall survival, cumulative incidence of relapse, non-relapsed mortality (NRM) and GvHD at 2 years after Allo-SCT * The impact of CMV infection and CMV reactivation on progression-free survival, overall survival, and NRM * Averse events of GVHD prophylaxis medication Participants will be collected the data of treatment and treatment response during transplant until 2 years after transplant from hospital medical record.
Interventions
None listed
Sponsors
Siriraj Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age more than 15 years * Diagnosis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), myelofibrosis primary and/or post PV/ET myelofibrosis, aplastic anemia, lymphoma, or paroxysmal nocturnal hemoglobinuria * Received HLA-matched related (MSD-HSCT) or unrelated allo-SCT (MUD-HSCT) or haploidentical hematopoietic stem cell transplantation
Exclusion criteria
* Insufficient data needed for analysis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with CMV infection and reactivation | 14 days to 6 months after transplant | Number of participants with CMV infection and reactivation after allogeneic hematopoietic stem cell transplantation Between Standard Regimen, Methotrexate plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Median overall survival | at 2 years after transplant | — |
| cumulative incidence of relapse | at 2 years after transplant | — |
| progression-free survival | at 2 years after transplant | — |
| GvHD | at 2 years after transplant | Number of participants who have GvHD symptom |
| Averse events | at 2 years after transplant | Averse events of GVHD prophylaxis medication |
| non-relapsed mortality | at 2 years after transplant | — |
Contacts
Primary ContactChutima Kunacheewa, MD
Backup ContactWeerapat Owatthanapanich, MD
Outcome results
None listed